Work

Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort (n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1-42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9-not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results. METHODS: Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety. RESULTS: With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16-48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9-15.8), and median OS was 15.9 months (95% CI: 10.4-22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%). CONCLUSIONS: With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.
Language: English
Subfield: Cancer Research
Open Access status: hybrid
Estimated APC paid: $4,590
OpenAlex ID: W7231767640
FWCI:
Cites: 15
Cited by:
Related to: 10